Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Cyclophosphamide, Fludarabine
CB-011 · 1 trial · 1 indication
Number of patients with DLTs during the 28 days following the first administration of CB-011.
The ORR will be evaluated by International Myeloma Working Group (IMWG) criteria.
| Arm | Type | Description |
|---|---|---|
| CB-011 | EXPERIMENTAL | * Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design. * Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A |
| Name | Type | Description |
|---|---|---|
| CB-011 | BIOLOGICAL | CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion |
Inclusion Criteria: 1. Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.) 2. Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a...
Top 20 of 25 competitors
CB-011 is an investigational CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy being developed for the treatment of relapsed/refractory multiple myeloma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
CB-011 targets BCMA, a protein expressed on multiple myeloma cells. It is a CRISPR-edited allogeneic CAR-T cell therapy designed to recognize and attack BCMA-positive tumor cells.
CB-011 is being developed by Caribou Biosciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol CRBU.
CB-011 is currently in Phase 1 clinical development. It is an investigational therapy and has not received FDA approval. The FDA has granted it Fast Track, Regenerative Medicine Advanced Therapy (RMAT), and Orphan Drug designations.
CB-011 is being evaluated in a Phase 1 clinical trial with the identifier NCT05722418. This trial is recruiting patients with relapsed/refractory multiple myeloma in the United States and has an estimated enrollment of 50 participants.
Yes, CB-011 is a CRISPR-edited allogeneic anti-BCMA CAR-T cell therapy. It is being studied in patients with relapsed/refractory multiple myeloma, and the ongoing clinical trial is titled 'CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma.'